Sponsorship will fund completion of monograph to guide commercial production in Canada
VANCOUVER, British Columbia, March 12, 2013 /CNW/ - Abattis Bioceuticals Corp (OTC PINK: ATTBF) (CNSX: FLU) today announced that it has provided $10,000 sponsorship for the cannabis (cannabis sp.) monograph and therapeutic compendium currently under development by the American Herbal Pharmacopoeia (AHP).
The monograph, scheduled for release in Spring 2013, will provide industry with a variety of scientifically valid analytical methods suitable for use in the identification, purity, and quality assessment of cannabis and its crude products.
Health Canada has recently proposed changes to the Canada's Marijuana Medical Access Program that aims to treat marijuana as it does any prescribed drug, allowing for legal commercial production for those who meet specific requirements.
"This generous sponsorship from Abattis Bioceuticals will facilitate the completion of this important and timely monograph," said Roy Upton, executive director of AHP. "There is a critical need for quality controls to be put in place in the cannabis industry to ensure valid and appropriate testing methodologies, and the AHP monograph will help to create greater transparency and establish standard methods of analysis."
"We are extremely proud to support the development of this monograph by AHP," said Mr. Michael Withrow, Abattis' chief executive officer. He went on to say, "There is a strong need for the development of transparent standards for cannabis and its products and an incredible need for objective and critical review of the therapeutic and safety data on cannabis, especially now as the laws are being changed to allow for multiple uses of this misunderstood botanical. The world needs standards for Cannabis and the many phytochemicals that come from it so lawmakers can properly categorize them and so formulators can legally apply the compounds in appropriate products that help those who are suffering from various chronic diseases."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp., based in Langley, B.C., is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of growing, producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in the pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high-growth areas of functional foods and dietary supplements business. For more information, visit the company's website at www.abattis.com.
About the American Herbal Pharmacopoeia
The American Herbal Pharmacopoeia is a non-profit 501C(3), California-based research organization with a mission to promote the responsible use of herbal products and herbal medicines through the production of critically reviewed monographs that outline the quality control criteria needed for ensuring the identity, purity, and quality of botanical raw materials. Founded in 1995, AHP has monographs on 35 different botanicals. For more information, visit AHP's website, http://www.herbal-ahp.org/index.html.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
Mr. Mike Withrow
Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. There can be no assurance that any forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or to revise them to reflect the occurrence of future unanticipated events.
SOURCE: Abattis Bioceuticals Corp.
For further information: